Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 3
2013 4
2014 1
2015 2
2018 2
2019 1
2020 2
2021 2
2022 7
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Raising Immunization Rates Among Cancer Patients.
Kiderlen TR, Trostdorf K, Delmastro N, Salomon A, Scholz CW, Späth-Schwalbe E, Mansmann V, Roll S, Reinwald M, Wit M. Kiderlen TR, et al. Among authors: scholz cw. Dtsch Arztebl Int. 2022 Jul 1;119(26):466-467. doi: 10.3238/arztebl.m2022.0167. Dtsch Arztebl Int. 2022. PMID: 36321685 Free PMC article. No abstract available.
International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkin lymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkin lymphoma (QLQ-NHL-LG20).
Oerlemans S, Efficace F, Kyriakou C, Freitas AC, Shamieh O, Creutzberg CL, Lehmann J, Petranovic D, Nagele E, Bredart A, Dong D, Scholz CW, Caocci G, Molica S, Griskevicius L, Xochelli A, Kieffer JM, Agelink van Rentergem JA, Alrjoub W, Mueller A, Gomes Da Silva M, Alves da Costa F, Malak S, Cocks K, van de Poll-Franse LV; EORTC Quality of Life Group. Oerlemans S, et al. Among authors: scholz cw. Cancer. 2023 Sep 1;129(17):2727-2740. doi: 10.1002/cncr.34822. Epub 2023 May 19. Cancer. 2023. PMID: 37204189
Breast Cancer-Associated Thrombotic Microangiopathy.
Regierer AC, Kuehnhardt D, Schulz CO, Flath B, Jehn CF, Scholz CW, Possinger K, Eucker J. Regierer AC, et al. Among authors: scholz cw. Breast Care (Basel). 2011 Dec;6(6):441-445. doi: 10.1159/000335201. Epub 2011 Dec 15. Breast Care (Basel). 2011. PMID: 22419897 Free PMC article.
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.
Fischer L, Jiang L, Dürig J, Schmidt C, Stilgenbauer S, Bouabdallah K, Solal-Celigny P, Scholz CW, Feugier P, de Wit M, Trappe RU, Hallek M, Graeven U, Hänel M, Hoffmann M, Delwail V, Macro M, Greiner J, Giagounidis AAN, Dargel B, Durot E, Foussard C, Silkenstedt E, Weigert O, Pott C, Klapper W, Hiddemann W, Unterhalt M, Hoster E, Ribrag V, Dreyling M. Fischer L, et al. Among authors: scholz cw. Leukemia. 2024 Jun;38(6):1307-1314. doi: 10.1038/s41375-024-02254-2. Epub 2024 Apr 27. Leukemia. 2024. PMID: 38678093 Free PMC article. Clinical Trial.
An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia.
Fiedler W, Montesinos P, Schliemann C, Middeke J, Vasu S, Scholz CW, Esteve J, Mondal S, Rüter B, Burkard U, Osswald A, Blum W. Fiedler W, et al. Among authors: scholz cw. Haematologica. 2022 Dec 1;107(12):2977-2982. doi: 10.3324/haematol.2022.281128. Haematologica. 2022. PMID: 36005556 Free PMC article. Clinical Trial. No abstract available.
International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27.
Oerlemans S, Efficace F, Shamieh O, Cardoso Borges F, de Jong C, Dong D, Lehmann J, Malak S, Petranovic D, Scholz CW, Caocci G, Molica S, Griskevicius L, Nagele E, Bredart A, Carvalho E, Xochelli A, Agelink van Rentergem J, Alrjoob W, Mueller A, Freitas AC, Cocks K, Creutzberg C, Kyriakou C, van de Poll-Franse L. Oerlemans S, et al. Among authors: scholz cw. Blood Adv. 2023 Nov 28;7(22):7045-7055. doi: 10.1182/bloodadvances.2023010841. Blood Adv. 2023. PMID: 37738090 Free PMC article.
International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia.
Oerlemans S, Efficace F, Kieffer JM, Kyriakou C, Xochelli A, Levedahl K, Petranovic D, Borges FC, Bredart A, Shamieh O, Gziskevicius L, Lehmann J, Scholz CW, Caocci G, Molica S, Stamatopoulos K, Panteliadou AK, Papaioannou M, Alrjoob W, Baliakas P, Rosenquist R, Malak S, Miranda A, Cocks K, van de Poll-Franse L; EORTC Quality of Life Group. Oerlemans S, et al. Among authors: scholz cw. Br J Haematol. 2022 May;197(4):431-441. doi: 10.1111/bjh.18072. Epub 2022 Mar 7. Br J Haematol. 2022. PMID: 35255152
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer.
Kuemmel S, Campone M, Loirat D, Lopez RL, Beck JT, De Laurentiis M, Im SA, Kim SB, Kwong A, Steger GG, Adelantado EZ, Duhoux FP, Greil R, Kuter I, Lu YS, Tibau A, Özgüroğlu M, Scholz CW, Singer CF, Vega E, Wimberger P, Zamagni C, Couillebault XM, Fan L, Guerreiro N, Mataraza J, Sand-Dejmek J, Chan A. Kuemmel S, et al. Among authors: scholz cw. Clin Cancer Res. 2022 Jan 1;28(1):106-115. doi: 10.1158/1078-0432.CCR-20-3955. Epub 2021 Oct 6. Clin Cancer Res. 2022. PMID: 34615719 Clinical Trial.
25 results